People · Operator
Named in public records as an officer, director or promoter · active 2008–2015 · Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Eiger Biopharmaceuticals Inc | — | Biotechnology | Series A | $70.9M | $216.9M | 2008 |
| Path Labs Holdings, LLC | — | Other Health Care | Pre-Seed | $500K | $15.4M | 2011 |
Jeffrey Glenn at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeffrey Glenn on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Nina Kjellson | 1 | 11 |
| Glen Sato | 1 | 4 |
| C Jason Payne | 1 | 4 |
| Thomas Dietz | 1 | 4 |
| Paul Truex | 1 | 3 |
| Peter Kolbeck | 1 | 2 |
| Keith Vendola | 1 | 2 |
| Wenjin Yang | 1 | 2 |
| Ed Engleman | 1 | 1 |
| David Cory | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.